Related Experiment Videos
[Gallium-67 scintigraphy in malignant lymphoma]
O Cohen-Haguenauer1, P Brice, M Gaci
1Service de Médecine nucléaire, Hôpital Saint-Louis, Paris.
Presse Medicale (Paris, France : 1983)
|March 27, 1993
Summary
Gallium-67 scanning effectively differentiates residual lymphoma masses, distinguishing fibrous tissue from active tumors. This non-invasive method guides further treatment decisions for Hodgkin and non-Hodgkin lymphoma patients.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Residual masses after lymphoma treatment pose a challenge in determining malignancy.
- Accurate assessment is crucial for guiding subsequent therapy decisions.
Purpose of the Study:
- To evaluate the utility of Gallium-67 scanning in differentiating post-treatment residual masses in lymphoma.
- To compare Gallium-67 scanning with Magnetic Resonance Imaging (MRI) for this purpose.
Main Methods:
- Gallium-67 scintigraphy was performed on 52 patients with residual masses after lymphoma treatment.
- Magnetic Resonance Imaging (MRI) was conducted on a subset of these patients, analyzing T2-weighted sequences.
Main Results:
- Gallium-67 uptake showed an excellent correlation with the progressiveness of tumoral masses.
- Low-intensity signals on T2-weighted MRI sequences indicated fibrous masses.
- High-intensity signals on T2-weighted MRI sequences were inconclusive for distinguishing fibrous from tumoral masses.
Conclusions:
- Gallium-67 scanning is a valuable, non-invasive tool for assessing lymphoma extension and characterizing residual masses.
- It accurately distinguishes between fibrous and active tumoral residual masses, aiding treatment planning.